Europe open: Stocks reverse early losses, healthcare leads
20th Jul 2020 07:56
(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.
Read moreOxford-AstraZeneca Covid-19 vaccine safe, produces immune response
20th Jul 2020 07:52
(Sharecast News) - The coronavirus vaccine being developed by AstraZeneca and the University of Oxford was found to produce both antibodies and T-cells and to be "safe, tolerated, and immunogenic", according to results of a phase 1 human trial published in The Lancet on Monday.
Read moreUK government secures 90 million doses of Covid-19 vaccines
20th Jul 2020 07:51
(Sharecast News) - The UK government has agreed to buy 90 million doses of coronavirus vaccines being developed by Pfizer and Biontech, and France's Valneva.
Read moreAstraZeneca Covid-19 vaccine shows promise - report
15th Jul 2020 11:42
(Sharecast News) - A Covid-19 vaccine backed by AstraZeneca is producing positive results in initial trials, according to a report.
Read moreJP Morgan says 'pent-up' demand will be exhausted, stays 'overweight' on Tech and Healthcare
13th Jul 2020 12:48
(Sharecast News) - Equity strategists at JP Morgan believe that second quarter corporate results on both sides of the Atlantic may come in ahead of analysts' forecasts, helped by the fact that estimates were at very depressed levels.
Read moreAstraZeneca gets EU approval for Lynparza
8th Jul 2020 07:18
(Sharecast News) - AstraZeneca announced on Wednesday, alongside its partner MSD, that 'Lynparza', or olaparib, has been approved in the European Union for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Read moreInovio Pharmaceuticals's Covid-19 vaccine triggers immune response
30th Jun 2020 18:34
(Sharecast News) - Inovio Pharmaceuticals's experimental vaccine against the novel coronavirus was found to be safe in an early stage clinical trial and successfully induced an immune response in the majority of participants in the test.
Read moreAstraZeneca neurofibromatosis treatment gets orphan drug designation in Japan
30th Jun 2020 08:07
(Sharecast News) - AstraZeneca said on Tuesday that selumetinib, its treatment for genetic disease neurofibromatosis type 1, has been granted orphan drug designation in Japan.
Read moreSingle course of Covid-19 treatment to cost $2,340 per patient - Gilead
29th Jun 2020 12:00
(Sharecast News) - Gilead Sciences has announced it will charge developed countries $390 a vial for remdesivir, its antiviral drug currently being investigated for use in Covid-19 patients.
Read moreAntibody levels of Covid-19 patients decline quickly, small study shows
22nd Jun 2020 12:54
(Sharecast News) - Levels of antibodies in people who have suffered Covid-19 reportedly falls sharply in the two to three months following their infection, a study showed, although the implications for patient immunity were unclear.
Read moreFriday broker round-up
19th Jun 2020 14:21
(Sharecast News) - Domino's Pizza Group: Berenberg downgrades to sell with a target price of 250p.
Read moreBerlin invests 300.0m euro in Covid-19 maker CureVac
15th Jun 2020 12:07
(Sharecast News) - Berlin unveiled a multi-million dollar investment into German biotechnology outfit CureVac, alongside dievini Hopp BioTech, SAP co-founder Dietmar Hopp's holding company.
Read moreAstraZeneca to provide Europe with 400m doses of Covid-19 vaccine, if successful
15th Jun 2020 07:05
(Sharecast News) - AstraZeneca inked a deal with for European countries to provide its Covid-19 vaccine, if successful, starting from the end of 2020.
Read moreUS to start studies into three vaccine candidates from July
10th Jun 2020 14:58
(Sharecast News) - Authorities in the US are planning to fund and conduct studies into three experimental vaccines for the novel coronavirus, including that being developed by Oxford University's Jenner institute and AstraZeneca.
Read moreAstraZeneca approached Gilead about merger - report
8th Jun 2020 07:33
(Sharecast News) - AstraZeneca has approached Gilead Sciences of the US about a potential merger to create a $240bn drugmaker, according to a report.
Read more